CARMIEL, Israel, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ (taliglucerase alfa) will be presented at the 9th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in Orlando, Florida. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.
"The data to be presented at the conference further reinforce the use of ELELYSO as a treatment option for Gaucher patients, including naïve Gaucher patients, and patients who were previously treated with imiglucerase (Cerezyme®)," stated Professor Ari Zimran, M.D., Director of the Gaucher Clinic in Shaare Zedek Medical Center, Jerusalem, Israel and lead clinical investigator. "With the approval of ELELYSO in Israel, I am pleased to be able to provide a new treatment option to my patients."
Gregory Pastores, M.D., Professor of Neurology and Pediatrics and Director of the Neurogenetics Laboratory at the New York University School of Medicine, is presenting long-term data from the Company's multi-center, open-label switchover extension trial of ELELYSO for the treatment of Gaucher disease. The Company's original switchover trial was a nine-month trial in which patients with stable disease were switched from treatment via intravenous infusions of imiglucerase (Cerezyme®) to intravenous infusions of ELELYSO every two weeks at an equivalent dose to the patient's previous imiglucerase dose. Patients who participated in the switchover trial were given the option to continue treatment with ELELYSO in the Company's switchover extension trial.Twenty-five adult patients completed the switchover trial, of which 19 elected to continue treatment with ELELYSO through the long-term extension trial. Five of the six patients who did not enroll in the extension trial continued nonetheless to receive ELELYSO through the Company's various compassionate use programs. One patient was unable to comply with the study protocol and therefore was not eligible to participate in the extension trial.